TRCT
ELVN icon

Tower Research Capital (TRC)’s Enliven Therapeutics ELVN Stock Holding History

Tower Research Capital (TRC)’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$136K Buy
3,471
+1,167
+51% +$32.3K ﹤0.01% 1932
2025
Q4 		$35.5K Buy
2,304
+728
+46% +$14.5K ﹤0.01% 2689
2025
Q3 		$32.3K Sell
1,576
-3,710
-70% -$74.8K ﹤0.01% 2879
2025
Q2 		$106K Buy
5,286
+3,490
+194% +$66.1K ﹤0.01% 2328
2025
Q1 		$35.3K Buy
1,796
+198
+12% +$4.26K ﹤0.01% 2487
2024
Q4 		$36K Buy
1,598
+1,114
+230% +$28.9K ﹤0.01% 2775
2024
Q3 		$12.4K Sell
484
-2,759
-85% -$63.9K ﹤0.01% 3595
2024
Q2 		$75.8K Buy
3,243
+2,737
+541% +$57.6K ﹤0.01% 2782
2024
Q1 		$8.9K Sell
506
-4,979
-91% -$76.4K ﹤0.01% 3935
2023
Q4 		$75.9K Sell
5,485
-1,270
-19% -$15.5K ﹤0.01% 2853
2023
Q3 		$92.3K Buy
6,755
+5,373
+389% +$90.5K ﹤0.01% 2040
2023
Q2 		$28.2K Sell
1,382
-275
-17% -$5.56K ﹤0.01% 3081
2023
Q1 		$36K Buy
1,657
+698
+73% +$14.2K ﹤0.01% 2807
2022
Q4 		$16K Buy
+959
New +$15.3K ﹤0.01% 3337
2022
Q2 		– Sell
-208
Closed -$2K – 6166
2022
Q1 		$2K Sell
208
-1,005
-83% -$6.63K ﹤0.01% 5536
2021
Q4 		$11K Buy
1,213
+684
+129% +$8.97K ﹤0.01% 4401
2021
Q3 		$9K Buy
529
+527
+26,350% +$10.9K ﹤0.01% 4428
2021
Q2 		$0 Sell
2
-446
-100% -$13.8K ﹤0.01% 5549
2021
Q1 		$15K Sell
448
-769
-63% -$39.1K ﹤0.01% 4102
2020
Q4 		$107K Buy
1,217
+36
+3% +$3.02K ﹤0.01% 2281
2020
Q3 		$96K Buy
1,181
+981
+491% +$88.5K ﹤0.01% 3171
2020
Q2 		$22K Buy
+200
New +$22.4K ﹤0.01% 3624

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tower Research Capital (TRC)'s ELVN Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Enliven Therapeutics (ELVN) stake by 51% in Q1 2026, buying an estimated $32.3K and bringing the position to 3,471 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #1932.

Tower Research Capital (TRC) first reported a position in ELVN in Q2 2020 and has held it in 22 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Tower Research Capital (TRC) held 3,471 shares of Enliven Therapeutics worth $136K as of Q1 2026.
  • Tower Research Capital (TRC) bought 1,167 Enliven Therapeutics shares in Q1 2026, an estimated $32.3K.
  • Enliven Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1932 holding.
  • Tower Research Capital (TRC) first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 22 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.